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ABSTRACT 
Busulphan (Bu) is an alkylating agent used in high-doses as part of the conditioning regimen prior to 
hematopoietic stem cell transplantation (HSCT). HSCT is a curative treatment for hematological 
malignancies and other disorders. Bu can be administered by oral or intravenous route. The 
intravenous formulation contains high concentrations of dimethylacetamide (DMA), a potent solvent, 
but both hepatotoxic and neurotoxic. High-dose Bu treatment was shown to induce hepatotoxicity, 
which can develop to sinusoidal obstruction syndrome (SOS). Another side effect of high-dose Bu 
treatment is convulsions or generalized tonic-clonic seizures. The general aim of this thesis was to 
investigate the pharmacokinetics of Bu and DMA including their metabolites and understand the 
mechanisms underlying their toxicities. 
In Study I. A liquid chromatography-mass spectrometry (LC-MS) based method was developed to 
quantify DMA and its primary metabolite methylacetamide (MMA) in human plasma. By following 
the FDA guidelines for bioanalytical method validation, we established a robust, selective, 
reproducible, and sensitive method for quantification of DMA and MMA.  The calibration curves 
were linear between 1 and 4000 µM, and the limits of quantification were 1.8 and 8.6 µM for DMA 
and MMA, respectively. The developed method can be used for occupational exposure studies as well 
as monitoring both compounds in patients receiving drugs where DMA is present as an excipient. 
In Study II. The pharmacokinetics of DMA and MMA was investigated in 18 pediatric patients 
receiving high-dose Bu treatment prior to HSCT. We used the LC-MS method developed in study I to 
quantify DMA and MMA in patients’ plasma. The results have shown accumulation of MMA 
throughout the treatment accompanied by an increase in the DMA clearance after the first dose 
administration of Bu. MMA had a slow elimination, and its half-life was calculated as 12.7h. In 
patients also, alanine transaminase (ALT) levels increased in more than 60% of the patients during 
conditioning with intravenous Bu. In vitro, cytotoxic tests on the hepatic cell line Huh 7 showed that 
the combination of Bu and MMA was more toxic than each compound separately. These findings 
imply that MMA might enhance Bu-induced hepatotoxicity. 
In Study III. We investigated Bu-induced seizures, a neurotoxicity associated with high-dose Bu 
treatment. We quantified Bu and its four metabolites, tetrahydrothiophene (THT), THT 1-oxide, 
sulfolane, and 3-OH sulfolane in 18 patients receiving Bu prior to HSCT. The results showed that 
sulfolane, and to a less extend 3-OH sulfolane, were accumulated in patients throughout treatment 
with Bu. Sulfolane remained detectable up to 60h after last Bu administration. In mice, generalized 
seizures occurred in the group administered with sulfolane. Furthermore, pharmacokinetic studies in 
mice organs and plasma showed a high distribution of sulfolane into the brain where the ratio AUC 
brain/AUC plasma was the highest and calculated as 1.45. Neurotransmitters analysis in mouse brain 
showed that GABA and calbindin 28k levels were decreased in the group of mice injected with 
sulfolane. The levels of sulfolane in patients might have a role in potentiating Bu-induced seizures. 
In Study IV. The role of N-acetylcysteine (NAC), a precursor of glutathione, on Bu-induced 
hepatotoxicity and the clinical outcome of HSCT was investigated. We evaluated the liver values, 
transplantation/conditioning complications and clinical outcome in two groups of patients receiving 
Bu (with and without NAC prophylaxis). The liver enzymes ALT, aspartate transaminase (AST) and 
alkaline phosphatase (ALP) were significantly decreased in the group of patients receiving Bu with 
NAC prophylaxis compared to the control group. Those levels were normalized even in patients who 
had high levels of liver enzymes before the start of Bu treatment. These observations suggest that 
NAC prophylaxis can potentially reduce Bu-induced hepatotoxicity without negatively affecting the 
clinical outcome of HSCT. 
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I.   INTRODUCTION 
1.   Cancer: definition and history 
According to the National Institute of Cancer (NCI), cancer is a group of diseases in which 
cells are dividing uncontrollably (excessive proliferation), invading the adjacent tissues, 
and spreading to other parts of the body (metastasis) via blood circulation and the 
lymphatic system [1, 2]. The word “cancer” is originated from the Greek word for crab, 
“Karkinos” and was coined by the Greek physician Hippocrates (460-370 BC). The term 
was adopted by the Romans (cancer in Latin means crab) to explain malignant tumors [3, 
4]. 
Historically, cancer is an ancient disease that has afflicted both humans and animals 
around the world. In fact, there is paleopathological evidence that exhibits the existence of 
cancer in prehistoric man and  animals such as dinosaurs [3]. The earliest description of 
cancer in humans was discovered in an Egyptian papyrus that was sold to the antiquities 
dealer and collector Edwin Smith in 1862 [5]. This ancient surgical document was placed 
in a tomb in Egypt over 3000 years ago. Written around 1600 BC, the papyrus described 
48 surgical cases of which 8 cases were breast tumors or ulcers; the document was based 
on an earlier reference dated 3000 BC. Other evidences of metastatic carcinoma were also 
found in the skeletons of mummies of ancient populations [6-10].  
According to The International Agency for Research on Cancer (IARC), which is a part of 
the World Health Organization, cancer is the second leading cause of death worldwide; i.e. 
in every six deaths, one is caused by cancer [11].  
2.   Theories of the cancer development  
Hippocrates established the first theory about the development of cancer as the humoral 
theory [4]. He believed that the human body consists of four types of fluids as humors 
(blood, phlegm, yellow bile and black bile) and that the correct balance between these 
humors is fundamental for maintaning the human health. Based on this theory, he 
described the development of cancer as a result of excess of dark bile in a particular body 
organ. The humoral theory was accepted for 1300 years and was dismissed during the 
middle ages [4]. Despite all, Hippocrates was the first to classify cancer to sarcomas and 
carcinomas. These terms are still used until today.  
After dismissing the humoral theory and until the 1920s, several other theories such as 
lymph theory, parasite theory, chronic irritation theory and trauma theory were proposed 
to explain the development of cancer [4].  Upon discovery of DNA helical structure by the 
Nobel laureates Watson and Crick in the middle of the 20th century [12], scientists began 
to gradually unravel the complexity of cancer biology. Subsequently, the discovery of the 
two important gene families during the 1970s, oncogenes (involved in promoting cancer 
development), and tumor suppressor genes (controlling the cell proliferation), have 
increased our understanding about  gene functions, transformations and mutations that can 
lead to different abnormalities, among them cancer [13-15]. 
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3.   Hematological malignancies 
Hematological malignancies, known also as blood cancer, represent a heterogeneous 
group of cancers that affect the blood, the bone marrow, and the lymphatic system. 
Nearly all the hematological malignancies originate from the bone marrow. As shown 
in Figure 1 and 2, depending on the affected cell types, they are classified as myeloid 
neoplasms (myeloid lineage, Figure 1), or lymphoid neoplasms (lymphoid lineage, 
Figure 2). Although a variety of classifications have been described in the literature, in 
2001, the World Health Organization (WHO) established a classification protocol that 
categorized and defined the different hematological malignancies according to their 
genetic abnormalities, morphological characteristics, and clinical features; this 
classification is updated every 8 years [16-19]. 
 
Figure 1: World Health Organization Classification (WHO) of Myeloid Neoplasms 
(Adapted and modified from [18]).  
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Figure 2: World Health Organization Classification (WHO) of Lymphoid Neoplasms 
(Adapted and modified from [19]). 
4.   Treatment of hematological malignancies 
A physics-based approach for the treatment of all hematological malignancies started in 
the beginning of the 20th century with the discovery of X-rays. The X-rays were used for 
palliative therapy in patients with Hodgkin disease [20]. On the other hand, the first 
chemical treatment for cancer was the systemic arsenic therapy performed by the Arab 
physician, Ibn Sina (known in the West as Avicenna) in the 11th century [21].The modern 
era of cancer chemotherapy began in the 1940s as a result of observing the side effects of 
mustard gas on white blood cells (WBCs) of soldiers exposed to this chemical during 
World War-I and further the adverse effects of the same compound seen on the lymph 
nodes and bone marrow during World War-II [22]. Goodman and colleagues were able to 
temporarily induce tumor regression in patients with non-Hodgkin lymphoma using the 
more stable nitrogen mustard compounds such as beta-chloroethyl amines [23]. By the end 
of the 1940’s, Sidney Farber introduced the second group of anti-cancer drugs, folate 
analogues (known as antimetabolites) for the treatment of acute lymphatic leukemia in 
pediatric patients. 
Today, more than 50 different chemotherapeutic agents categorized into 14 different 
classes are used for the treatment of hematological malignancies (Table 1) [24]. These 
agents are often used in different combinations depending on the diagnosis and prognosis 
of the malignancy as well as the age and health status of the patient. Based on these 
multidrug treatments, more than 70% of children with ALL and about 80% of children and 
adults with Hodgkin lymphoma are cured [24].   
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Treatment Mechanism of action Usage Example of Drugs 
Alkylating 
agents 
Alkylate nucleic acids 
and cause apoptosis      
Lymphoma, 
myeloma, 
leukemia  
Busulphan (myleran ®, 
Busulfex®), 
Cyclophosphamide 
(Cytoxan®,Neosar®)  
Antitumor 
antibiotics 
Interact with DNA and 
reduce cell survival   
All blood 
cancers   
Doxorubicin (Adriamycin ®, 
Rubex ®), Bleomycin 
(Blenoxan®) 
Antimetabolite
s 
Inhibit DNA /RNA 
synthesis and induce 
cell death     
Most blood 
cancers   
Fludarabine (Fludara®), 
Methotrexate   
Antimitotic 
drugs 
Inhibit the mitosis and 
induce apoptosis      
Lymphoma Vinblastine (Velban®), 
Paclitaxel (Taxol®)   
Bisphosphonat
es 
Prevent the bone 
resorption in myeloma 
Myeloma  Pamidronate (Aredia®), 
Zoledronic acid (Zometa ®) 
Synthetic 
hormones 
At high doses, kill 
malignant lymphocytes 
Lymphoma Dexamethason 
(Decadron®),Prednisone 
(Deltasone®) 
DNA-repair 
enzyme 
inhibitors 
Target DNA repair 
enzymes and cause 
apoptosis 
Lymphoma, 
leukemia  
Etoposide (VePesid®, 
Etopophos®, 
Toposar®),Topotecan 
(Hycamtin®)  
Histone 
deacetylase 
inhibitors 
Inhibit histone 
deacetylase, induce 
histone 
hyperacetylation and in 
cause cell death 
Leukemia  Vorinostat (Zolinza®)  
Monoclonal  
antibodies 
Target specific 
molecules on the 
malignant cells and 
cause apoptosis    
Lymphoma, 
leukemia  
Rituximab (Rituxan ®), 
Gemtuzumab (Mylotarg®) 
Bio modifiers Exert immune or 
antiangiogenesis 
effects    
Some blood 
cancers  
Interferon-ɑ (Roferon®A, 
Intron®A), Thalidomide   
Cell-maturing 
agents 
Cause maturation in 
leukemia cells  
 Leukemia  Tretinion (Vesanoid®), 
Arsenic trioxide (Trisenox®)  
Phototherapy 
drugs 
Stop malignant cell 
transformation by 
blocking mutant 
proteins  
Skin 
lymphoma  
Psoralen  
Tyrosine 
kinase  
inhibitors 
Tyrosine kinase  
inhibitors 
 Leukemia  Imatinib (Gleevec®), 
Dasatinib (Sprycel™) 
Proteasome 
inhibitors 
Inhibit the proteolytic 
function of 
proteasomes  
 Myeloma Bortezomib (Velcade®) 
Table 1: Classes of drug-based modalities used in the treatment of hematological 
malignancies (Adapted and modified from [24]). 
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5.   Hematopoietic stem cell transplantation  
Although the employment of chemotherapy in hematological malignancies has considerably 
improved the cancer treatment and increased the survival rate, the development of multidrug 
resistance or MDR (primary or acquired) [25, 26] has limited the success of curative potency 
of the chemotherapeutic agents. To improve treatment efficacy for hematological diseases 
and avoid the development of MDR, hematopoietic stem cell transplantation (HSCT) was 
introduced as a curative therapy for several hematological malignancies including those that 
are refractory to the conventional therapy [27-29]. Moreover, this treatment strategy is used 
for many acquired and congenital disorders of the hematopoietic system, as well as several 
immune and metabolic disorders [27-29]. The principle of HSCT lays in the replacement of 
the malignant/unhealthy hematopoietic stem cells in the patients either with their own healthy 
(isolated after induction treatment –autologous cells), or with other healthy donor stem cells 
(allogeneic or syngeneic). The first successful stem cell transplantation was performed by 
E.D. Thomas and his co-workers in 1959 [30]. The patient had an advanced stage of leukemia 
and received a preparative treatment with total body irradiation followed by infusion of bone 
marrow from her healthy identical twin (syngeneic HSCT). The transplant was successful and 
had a three-month remission [30]. Upon identification of the major histocompatibility 
complex molecules and typing of human leucocytes antigen (HLA)[31], several allogeneic 
bone marrow transplantations were successfully performed in the early 1960s [28, 32]. 
Currently, more than 40 000 allogenic HSCTs are performed in Europe annually [33]. The 
process of HSCT involves three main phases including; 
1). Conditioning of the patient depending on the diagnosis and prognosis, the patient receives 
a specific conditioning treatment for the purposes of abolishing the bone marrow 
(myeloablation) and in some cases eliminating the malignant cells. The patient conditioning 
can also have a purpose of suppressing the recipient’s immune system (immunosuppression) 
[34, 35]. While myeloablation creates space for the new marrow, immunosuppression allows 
the engraftment and prevents the rejection of the transplanted marrow [34].  
2). Intravenous infusion of HSCs which can be harvested from the bone marrow, peripheral 
blood or cord blood [34]. 
3). Monitoring the engraftment of the new marrow and determining the outcomes of HSCT 
[34].  
Regarding the last stage, it is well known that although HSCT can be a curative treatment 
strategy, its efficacy is far from being satisfactory.  For instance, several acute and/or chronic 
complications may emerge post HSCT [34, 35]. In fact, the occurrence and development of 
these complications (as detailed bellow) can hamper the success of HSCT [34-36].  
6.   Conditioning regimens, the good and the bad in HSCT 
Conditioning regimen is a key element in both allogeneic and autologous HSCT.  Treatment 
combination, protocol, length, and dosage of the selected drug/radiation depend on the 
transplantation center, diagnosis, age, remission and health status of the patient.  
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This preparative treatment can consist of various combinations of different myeloablative 
and immunosuppressive chemotherapeutic agents, with or without total body irradiation 
(TBI).   
The aim of conditioning regimens with high intensity is to eliminate, or strongly reduce 
the number of malignant cells in order for the donor marrow to regenerate hematopoiesis 
in the cancer patients. [28]. However, as it became evident that donor immune cells play a 
substantial role against tumor cells in the host (graft-versus-tumor (GVT) effect), many 
investigators reduced the dose of radiation and chemotherapeutic agents used in the 
conditioning regimens in order to enhance the GVT effect [37]. Today conditioning 
regimens can be divided into three main categories: myeloablative (MAC), reduced-
intensity (RIC), and non-myeloablative (NMAC): 
1. Myeloablative Conditioning (MAC) generally involves a combination of cytotoxic 
drugs that are given at maximally tolerated doses in order to eliminate the recipient’s 
hematopoietic cells in the bone marrow. This type of regimen is associated with high 
myelotoxicity, and mainly includes combination of high doses of busulphan (Bu), 
cyclophosphamide (Cy), melphalan, thiotepa (TT), and etoposide with or without TBI. 
Some years ago, fludarabine was introduced to substitute cyclophosphamide in the 
combination (Bu/Cy) in order to minimize the Cy-related toxicities. Today, busulphan in 
combination with fludarabine is being used frequently [38, 39]. Another conditioning 
regimen designed to provide anti-lymphomal activity is the BEAM, which is a 
combination of the four alkylating agents: carmustine (BiCNu®), etoposide, cytarabine 
(Ara-C), and melphalan [38]. 
 2. Reduced Intensity Conditioning (RIC) was introduced mainly to condition old 
patients who cannot tolerate the toxic effects of high dose treatment.  Patients with 
diseases that are associated with high rates of non-relapse mortality (e.g., Hodgkin’s 
disease and myeloma) also receive RIC  [40, 41]. Today RIC is also used for several 
metabolic and genetic disorders in pediatric patients [42]  
3. Non-Myeloabletive Conditioning (NMAC) induces less organ toxicity as it might 
reduce the risk of acute graft versus host disease (GVHD) by limiting the release of 
inflammatory cytokines and minimizing cytopenia [38].  
Despite being a key component of HSCT, conditioning regimens are considered as the 
main risk factor for the development of many of acute and chronic HSCT-associated 
complications (Table 2) [36, 43] In fact, these complications, in particular GVHD, relapse 
in malignancy, infections and drug-induced toxicities are the main causes for an increased 
mortality and morbidity following HSCT [35, 44]. 
7.   Busulphan, a key component in conditioning regimens for HSCT  
Busulphan (1, 4-butanediol dimethanosulfonate) is a bifunctional alkylating agent 
originally used at low doses for the treatment of some hematological malignancies such as 
chronic myeloid leukemia (CML) and polycythemia Vera (PCV) [45-47]. However, at 
high doses, busulphan has been a potent myeloablative agent (comparable to TBI) in 
conditioning regimens prior to HSCT [41, 48].  As part of various conditioning protocols, 
busuphan is either used orally or intravenously in doses of 0.8-1 mg/kg four times daily for 
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two to four days [49]. Busulphan exerts its cytotoxic effects by inter or intra-strand DNA 
crosslinking mainly at guanine N7 position causing a disturbance in DNA replication and 
leading to cell death [50, 51].  
Busulphan is mainly metabolized in the liver via conjugation with a key tripeptide 
antioxidant, glutathione (GSH) [52]. This conjugation is catalyzed by the glutathione S-
transferase isoforms GSTA1, GSTM1, GSTP1, and GSTT1 (Figure 3) [53]. The formed 
conjugate, Bu-sulfonium ion of GSH, is unstable and rapidly broken down (non-enzymatic 
reaction) to form tetrahydrothiophene (THT).  The conversion of Bu-sulfonium ion of GSH 
to THT can also be catalyzed by cystathionine gamma lyase (CTH) (Figure 3) [54]. The Bu-
sulfonium ion of GSH conjugate can also form THT by the alternative mercaptopurate 
pathway forming N-acetylated-cysteine conjugate, a reaction that is catalyzed by the 
enzymes, dipeptidase/cysteinylglycinase (DPEP), gamma glutamyl transfrase (GGT) and N-
acetyl transfrase (NAT) (Figure 3)[55]. An intermediate product of mercaptopurate pathway, 
THT-A (cysteine-S-conjugate [β-(S-tetrahydrothiophene L-alanine)], can undergo enzymatic 
conversion to form THT facilitated by CTH [56]. Furthermore, an in vitro study has shown 
that THT-A can slowly undergo a non-enzymatic beta-elimination reaction at pH 7.4 and 
37oC to yield THT [56].  Finally, the formed THT is rather a lipophilic compound, and 
subsequently undergoes an oxidation to produce tetrahydrothiofene 1-oxide (THT 1-Oxide) 
(Figure 3). Cytochrome P 450 (CYP2C9) and Flavin-containing monooxygynase 3 (FMO3) 
were found to be involved in THT metabolism [57, 58]. The THT 1-oxide itself undergoes 
further oxidation resulting in the formation of sulfolane, a product that is further oxidized to 
form 3-hydroxysulfolane (Figure 3)[59-61] [55, 58]. Although busulphan is a lipophilic 
compound, some of it can be hydrolyzed in  aqueous environment and converted to 
tetrahydofurane releasing  methane sulfonic acid (Figure 3) [62]. 
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Figure 3:  Metabolic pathway of busulphan. 
Several pharmacokinetic studies have revealed a wide inter- and intra-individual variation 
of bioavailability in patients receiving busulphan orally [63]. The variability observed in 
busulphan kinetics was more pronounced in children compared to adult patients [59, 64-
66]. Moreover, these studies have shown a great variability in drug exposure in those 
patients. Other studies have shown that low drug exposure can lead to engraftment failure 
and relapse while high exposer can be associated with the development of hepatic 
sinusoidal obstruction syndrome (SOS), formerly known as hepatic veno-occlusive disease 
(VOD) (Figure 4) [63-66]. In another investigation, a positive correlation was found 
between high plasma levels of busulphan and the increase of transplant-related mortalities 
(TRM) [67]. The optimal therapeutic window of busulphan was identified for a target 
concentration range of 600-900 ng/mL at a steady state (Figure 4) [55]. Thus, in patients 
with myeloid malignancies, therapeutic drug monitoring (TDM) and dose adjustment are 
recommended in order to reach the targeted drug exposure, which might result in better 
transplantation clinical outcome [65, 68]. With respect to busulphan toxicity, the major 
general and life-threatening complication associated with this drug is the development of 
SOS [49, 69]. Moreover, since busulphan is a lipophilic drug that can easily cross the 
blood-brain barrier (BBB) [70], neurotoxicity is also considered as an adverse effect of 
this drug [69, 71]. Indeed, one of the indications of busulphan-induced CNS toxicity is the 
development tonic-clonic seizures (busulphan-induced seizures) that occurs during the 
third and fourth days of conditioning in patients undergoing HSCT [72]. In order to avoid 
these CNS-related side effects, the conditioning regimen is accompanied with 
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anticonvulsant prophylaxis such as phenytoin, lorazepam, levetiracetam, or others [71-73]. 
However, studies have shown that the use of phenytoin increased busulphan clearance [71, 
74, 75]. Moreover, it has been reported that seizures occurred in 1.3% of patients despite 
treating concomitantly with anticonvulsant prophylaxis [76]. Thus, further studies are 
required to elucidate the mechanisms underlying the development of busulphan-induced 
neurotoxicity and to develop better preventive strategies for this HSCT-associated 
complication.  
 
Figure 4: The therapeutic window of busulphan. 
8.   Dimethylacetamide, a solvent in the intravenous busulphan formulation 
Since busuphan is a water insoluble drug, its intravenous preparation requires a potent 
solvent [77]. Currently, the available intravenous buslphan (Busulfex™) is dissolved in 
33% wt/wt dimethylacetamide (DMA) and 67% wt/wt polyethylene glycol 400. This 
formulation was developed by B.S. Andersson and co-workers to minimize the inter-
individual variations observed by the treatment with oral busulphan, particularly in 
pediatric patients  [63, 78]. Although the administration of the i.v. formulation has 
decreased the inter- and intra-individual variability of busulphan pharmacokinetics, the 
variability is still considerable [78, 79], [80]. Thus, intensive monitoring and dose 
adjustment is required for patients receiving busulphan, orally or intravenously, to 
improve the outcome of HSCT.  
DMA (CH₃CN (CH₃)₂) is an organic colorless solvent that is used to dissolve high 
molecular-weight polymers and a wide range of organic and inorganic compounds. 
Because of its excellent solvent properties, DMA is widely used in chemical and 
pharmaceutical industries for the production of films, acrylic and elastane fibers as well as 
in the manufacturing process of some antibiotics such as cephalosporin.  
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In the 1960s, DMA was studied as a potential anti-tumor drug; however, severe liver 
toxicities (shown by elevated transaminase) along with neurotoxicity (manifested as 
hallucinations, confusion, and lethargy) were revealed [81]. These adverse reactions were 
observed at a dose around 400 mg/kg/day [81]. Most of the patients included in phase I 
studies experienced other side effects like nausea and vomiting. Additionally, studies have 
shown that DMA induced hepatic injury in workers exposed to DMA during spandex 
fibers manufacturing process [82].  
In patients receiving intravenous busulphan, DMA can reach very high plasma levels, 
around 166 mg/kg/day, which represent 42% of the maximum tolerated dose (MTD). 
Whether or not these high plasma levels exert hepatotoxicity remains to be further 
investigated. Moreover, there is a lack of knowledge about the metabolism of DMA 
although it has been reported that DMA is metabolized in the liver by Cytochrome P450 
2E1 (CYP2E1) to N-methylacetamide and acetamide [83]. 
9.   N-acetylcysteine, a potential hepato-protective agent for conditioning-induced 
hepatotoxicity in HSCT 
N-acetylcysteine (NAC) is an old and affordable nutritional supplement/medication [84, 
85]. NAC is a thiol-containing compound that promotes glutathione biosynthesis and acts 
as a free radicals scavenger [86]. NAC is a stable, membrane permeable delivery system 
of cysteine (Figure 5). Upon administration, NAC undergoes deacetylation by 
deacetylases and provides L-cystein, which is one of the three essential amino acids for 
GSH synthesis (Figure 5) [87, 88]. NAC was first introduced as a mucolytic agent for 
treatment of lung diseases such as chronic bronchitis and cystic fibrosis [89, 90]. It is also 
used as a supporting treatment in combination with clomiphene citrate (CC) in CC-
resistant polycystic ovary syndrome (PCOS) [91]. One of the most common uses of NAC 
is in treatment of acetaminophen-induced hepatotoxicity [92, 93]. Oxidative stress plays a 
pivotal role in neurodegenerative diseases; accordingly and with reference to different 
studies, NAC is also used to treat several neurological diseases [94, 95]. In HSCT, NAC is 
used as a prophylactic drug given concomitantly with cytostatic drugs such as busulphan. 
It has been shown that NAC might exert a protective effect for post transplantation 
complications such as sinusoidal obstruction syndrome (SOS) [96-98]. The main 
characteristics of conditioning-induced SOS include hepatomegaly, hyperbilirubinemia, 
ascites and weight gain that emerge 21-30 days after HSCT [99, 100]. SOS is a potentially 
lethal complication, and its incidence ranges from 5% to over 50% [101]. Thus, it is of 
high importance to establish preventive and therapeutic strategies to decrease the 
incidence of SOS, and thereby improve overall survival of patients undergoing HSCT. 
Busulphan metabolism consumes large amounts of GSH [102] causing the depletion of the 
latter can contribute to the development of SOS [103]. In line with that, it has been shown 
that GSH infusion to rats with SOS prevented the development of the disease [97]. 
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Figure 5: NAC as a cysteine delivery system for GSH biosynthesis.  
10.   HSCT, an incomplete journey 
In the 60 years since the first report on HSCT, the use of this treatment procedure for 
hematological malignancies and other blood disorders has increased dramatically. Indeed, 
the data from the Worldwide Network for Blood and Marrow Transplantation (WBMT) 
has shown that until 2012, more than 1,000,000 HSCT were performed at 1516 transplant 
centers in 75 countries [104]. Moreover, the results of HSCT are improving constantly; for 
instance, the overall mortality and the risk for developing transplant-related complications 
(such as GVHD, infections, and organ toxicity) have been significantly reduced [105]. 
Unfortunately, despite all improvements, significant morbidity and mortality still occur in 
many patients after HSCT. This clearly suggests that there are still some unresolved issues 
related to patients’ response to different treatment strategies which results in alteration of 
treatment efficacy and lack of complete remission of patients.  The findings presented in 
this thesis focus on unraveling busulphan, DMA and metabolites-related toxicities, 
including toxicity due to its metabolites and to excipients. Unravelling and understanding 
the toxicities connected to the conditioning agents, will hopefully benefit patients 
undergoing HSCT. 
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II.   AIMS 
 
General Aim 
The overall aim of the study is to investigate the metabolism and the pharmacokinetics 
around busulphan treatment as part of the conditioning regimen prior to hematopoietic 
stem cell transplantation (HSCT), and elucidate the mechanisms underlying some of 
busulphan-related side effects.  
 
 
Specific Aims 
 
•   To develop a robust and sensitive bioanalytical method for quantification of 
dimethylacetamide (DMA) and methylacetamide (MMA) in biological matrices. 
 
•   To investigate the pharmacokinetics and the toxicity of DMA and its metabolite 
MMA in patients receiving intravenous busulphan. 
 
•   To explore the mechanisms of neurotoxicity caused by busulphan and/or its 
metabolites. 
 
•   To evaluate the beneficial effects of N-acetylcysteine (NAC) on the hepatotoxicity 
and the clinical outcome of HSCT in patients receiving busulphan as part of 
conditioning regimen.  
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III.   METHODOLOGY 
1.   Ethical implications 
The content of this thesis describes findings from patients with hematological disorders. 
The samples collection from those patients was primarily for dose adjustment purposes of 
busulphan prior to HSCT at Drottning Silvias Barn och Ungdomssjukhus in Gothenburg, 
Sweden (study I and II) and the Center for Allogeneic Stem Cell Transplantation 
(CAST), Karolinska University Hospital in Huddinge (study III and IV). The further 
use/analysis of the samples, extra-samples and clinical data in study I, II, III, and IV was 
approved by the Regional Ethical Committee in Stockholm, and informed consents were 
obtained from the patients, parents, or legal guardians (Ethical Permits #: 616/03, 65/03). 
The design of the animal experiments in paper III followed the principles of the 3Rs: 
replacing, reducing and refining. The animal experiments were performed after receiving 
the ethical approval from the Board of Agriculture in Stockholm (Ethical Permit #: ID 
619).  
2.   High performance liquid chromatography-electrospray ionization mass 
spectrometry 
Mass spectrometry is an analytical tool that can provide qualitative and quantitative 
information about the compound analyzed. The analyte can acquire positive/negative 
charges in the ionization chamber of the mass spectrometer; this step is called ionization. 
In the electrospray ionization mass spectrometer (ESI-MS), the ions are transformed from 
the solution to gaseous phase using electrical energy. Later on, the ionic species travel 
through the mass analyzer arriving to the detector where different signals are generated 
according to their mass/charge ratio (m/z). Those signals are recorded and graphically 
displayed on a computer system as a spectrum. The mass spectrum represents the relative 
abundance of the ions according to their m/z [104].  
In study I, we validated a bioanalytical method using a Finnegan TSQ Quantum Ultra 
triple quadrupole mass spectrometer (MS) with electrospray ionization (ESI) coupled with 
high performance liquid chromatography (HPLC). Detecting and quantifying DMA and 
MMA, was achieved using a YMC Pack ODS-AQ/S-5 µm for separation and two mobile 
phases, acetonitrile (Phase A) and water (Phase B) with 0.1% formic acid. In order to 
acquire sensitivity, we optimized and tuned the MS parameters by flow injection analysis 
(Table 2). 
Parameter Value 
Mode Positive (+) 
Ion spray voltage 5000 V 
Sheath gas 20 arbitrary units 
Auxiliary gas 5 arbitrary units 
Capillary temperature 237 oC 
Table 2: Optimization of different MS parameters for detection and quantification of 
DMA and MMA. 
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3.   Patients’ samples analysis 
In study I and II we used the validated HPLC-MS (ESI) based method to elucidate the 
pharmacokinetics of DMA and MMA. Therefore, we analyzed plasma samples from 
patients with different blood malignancies and other disorders. Those patients received 
high-dose intravenous busulphan (Busulfex) for a total period of four days followed by 
HSCT. In study III, samples (plasma and urine) were collected from patients who 
received oral busulphan prior to HSCT. We measured the concentrations of four 
busulphan metabolites, THT, THT 1-oxide, sulfolane, and 3-OH sulfolane, using gas 
chromatography mass spectrometry (GC-MS), a method that was developed by El Serafi 
et al [61]. The combination of GC and MS is ideal for generating quantitative and 
qualitative data for volatile and semi-volatile organic compounds. The method allowed us 
to follow the kinetics of the four metabolites in plasma and urine samples from 18 patients 
during the four days treatment with busulphan and 24h 48h and 72h after the last dose 
administration.  
4.   Patients’ clinical data analysis 
Large volumes of important clinical data are generated daily on clinical care sites. The 
secondary use of this clinical information can improve and help understanding and 
answering the questions around many diseases and treatments. In this thesis, we performed 
retrospective analysis and compared a set of clinical data in patients treated with 
busulphan prior to HSCT. In study II we performed a comparison of different liver 
enzymes levels, such as ALT, AST and bilirubin, before and after treatment with 
intravenous busulphan. We also made the correlation between those levels and the clinical 
data from the patients, i.e., the outcome of transplantation and the occurrence of 
transplant/conditioning-related complications. Study IV included clinical data from 108 
patients. In this study, the levels of the liver enzymes ALT, AST, ALP, and bilirubin were 
routinely measured and compared before and after busulphan conditioning in two groups, 
with and without prophylactic treatment with NAC. The clinical outcome of HSCT (i.e. 
relapse, graft failure, GVHD, SOS, and survival rate) was also compared in both patients 
groups.  
5.   Animal experiments and samples analysis 
The use of animals for medical research is a longstanding practice. The physiological 
similarities between animals and humans have allowed investigating and understanding a 
large number of diseases, mechanisms, and novel therapies [107]. Mouse as an 
experimental animal model, has been mostly used by researchers not only to provide 
insight into elucidating different mechanisms underlying different diseases, but also to 
study the toxicology and pharmacology of potential candidate drugs before the transition 
to human testing [108]. 
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[105] 
 
The appropriate selection of the animal and strain is very important for different types of 
studies [105]. In order to understand the neurological side effects of busulphan and its 
metabolites, in study III, we used the mouse strain C57BL/6N because it is commonly 
used for behavioral studies [106]. The animals (kept in standard housing conditions) 
received busulphan or one of the four metabolites (THT, THT1-oxide, sulfolane, and 3-
OH sulfolane) intraperitoneally, and were closely monitored and video recorded for 
different behavioral changes including the occurrence of seizures.  
In the same study (study III), we used the same mouse strain to investigate and follow the 
kinetics of busulphan and the four metabolites in plasma and different organs. Measuring 
the levels of these compounds at different time point using a GC-MS based method 
developed by El-Serafi et al [61], would help identify the compounds responsible for the 
behavioral changes and occurrence of seizures. Furthermore, we analyzed mice brains for 
different neurotransmitters such as, serotonin, dopamine, glutamate, GABA, and calbindin 
D28K. The measurements of the neurotransmitters were performed using commercially 
available enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s 
instructions. 
6.   Cell proliferation and cytotoxicity assay 
Cell culture or in vitro studies are the one key to the replacement and refinement of animal 
experimentation. It has been a rapid way of toxicological testing and screening of many 
candidate drugs for different diseases [107]. In study II, we performed cytotoxicity tests 
on two cell lines. As DMA was reported to have hepatotoxic effects [81], we decided to 
perform cell proliferation assay using the hepatic cell line Huh 7 after incubation with 
DMA, MMA and busulphan. We also investigated the cytotoxicity of those compounds in 
the promyelocytic leukemia cell line, HL-60. For monitoring the cells proliferation and 
viability in response to DMA, MMA, and busulphan at different concentrations and 
combinations, we used the tetrazolium based assay, WST-1. WST-1 is based on measuring 
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the activity of mitochondrial dehydrogenases that convert tetrazolium salt to formazan. 
The increase of formazan represents the correlation to the metabolically active cells [108].   
7.   Statistical analysis 
In study I, the values are expressed as means ± standard deviation (STDV) for each step 
of the validation, the STDV was also converted to coefficient of variation (CV %) for each 
parameter (i.e. accuracy, reproducibility, stability, recover). In study II and IV we used a 
non-parametric t-test, or Mann Whitney to compare liver enzymes levels in two groups 
using GraphPad Prism 5. The same t-test was used further in study II for comparing AUC 
and clearance in two groups, after 1st dose and after 8th dose administration of busulphan. 
The different compounds concentrations measured patients specimens, in study II and III, 
were plotted using GraphPad Prism 5 and expressed as mean ± SEM. Animal experiments 
data analysis were expressed as mean ± SEM. The cytotoxicity in study II was estimated 
by calculating the half maximal inhibitory concentration (IC50), using nonlinear regression 
analysis (fit curve) on GraphPad Prism 5. All the pharmacokinetic parameters in study II 
and III were estimated using the PK/PD software WinNonLin.
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IV.   RESULTS AND DISCUSSION 
1.   Study I 
DMA is a powerful solvent widely used in chemical and pharmaceutical industries to 
dissolve compounds with limited water solubility. In pharmaceuticals, DMA is used in the 
manufacturing process of certain antibiotics (i.e. cephalosporin)[109], and as an excipient in 
some drug preparations such as i.v busulphan (Busulfex or Busilvex), teniposide (Vumon), 
and Amsacrine (Amsidine)[110-112]. DMA has shown antitumor effects in vitro and in vivo 
[113, 114]. In patients, a phase I study of DMA has revealed that its administration exerted 
antitumor effects where two patients have shown response to the treatment [81]. Moreover, a 
recent study has shown that DMA acts as a bromodomain ligand, and therefore induced anti-
osteoporotic and anti-inflammatory effects [115].  During the phase I clinical trials, DMA 
revealed several toxicities (i.e. hepatotoxicity, neurotoxicity), and some of those toxicities 
were seen in spandex fibers workers [82]. Accordingly, following the pharmacokinetics of 
this compound in biological matrices is important due to its impact on safety and human 
health. Therefore, several methods have been developed to quantify DMA in plasma using 
GC-MS and LC-MS [116, 117]. MMA, the primary metabolite to DMA, was also quantified 
previously in urine from workers occupationally exposed [118]. We developed and validated 
an LC-MS based method according to the FDA guidelines for bioanalytical method 
development [119]. We validated this method in human plasma, and the results obtained 
from the accuracy, reproducibility, stability, and recovery tests, have met the criteria 
described in the guidelines (Table 3). Furthermore, the sample preparation is fast and simple, 
and allows a relatively quick quantification of DMA and MMA in the same sample 
simultaneously using the same instrument parameters and internal standard, DMA-d9. The 
limits of quantification (LOQ) for DMA and MMA were 1.8 µM and 8.6 µM, respectively. 
The calibration curves were linear for both compounds and cover a concentration range 
between 1 and 4000 µM (12 points/concentrations); the correlation coefficient was r2=0.9966 
for DMA, and r2=0.9911 for MMA. These values represent the sensitivity of our method and 
the ability to measure not only low plasma concentrations of these two compounds, but also 
relatively high concentrations which can also be used for environmental analysis. In 
conclusion, the new LC-MS method is a reproducible, sensitive, selective and robust tool 
that can be used in further investigations about DMA and MMA. It can also be used in 
occupational exposure studies in workers of different DMA-related products manufacturing. 
In a clinical setting, patients receiving high-dose Bu treatment are exposed to high 
concentrations of DMA; our method can help monitor the exposure in this group of patients 
and therefore avoid undesirable side effects. 
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Validation Parameter DMA CV (%) MMA CV (%) 
Accuracy 0.74 -2.92% 
 
 
6.67 - 8.16% 
Reproducibility 1.51 - 5.42% 2.14 - 6.90% 
Stability 4o C 1.24 - 3.52% 2.01 - 5.24% 
Stability -20o C 1.94 - 6.75% 3.43 - 4.50% 
Post Preparation 0.89 - 3.00% 4.30 - 14.03% 
 DMA (%) MMA (%) 
Recovery 97-100% 76-100% 
Table 3: Summary results for the bioanalytical method validation parameters 
CV=Coefficient of variation (Lowest-Highest). 
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2.   Study II  
High-dose busulphan treatment is an essential part and one of the most common conditioning 
regimens administered to patients prior to HSCT. Patients receiving oral busulphan have 
shown a large intra-individual variation; therefore, the i.v formulation was introduced to 
assure high bioavailability and minimize the variability between individuals [78, 110, 120]. 
DMA is present at high concentrations in the i.v formulation of busulphan, and the total dose 
for 4 days treatment is approximately 1 g/kg (for 16 mg/kg total dose of busulphan). It has 
previously been reported that DMA exerts several toxic effects such as gastrointestinal 
toxicity (nausea, vomiting, and anorexia) [81]. Several patients displayed hepatotoxicity 
during phase I studies of DMA when administered with 400 mg/kg/day for 3 days [81]. The 
same dose of DMA induced neurotoxic effects manifested in depression, lethargy, confusion 
and hallucinations [81]. During conditioning treatment, patients receive between 3.2-4.8 
mg/kg/day of busulphan over 4 days depending on the body weight; this dosage translates to 
166-248 mg/kg/day for four days of DMA which represents 42-62% of the maximum 
tolerated dose [121-123]. It is possible that there is a relative contribution of DMA and/or its 
metabolite MMA to the hepatotoxicity and neurotoxicity-related to busulphan conditioning. 
Accordingly, the results in our study have revealed that MMA, the primary metabolite of 
DMA, was accumulated in patients receiving i.v busulphan and still detectable even 40h 
after the last dose administration. In contrast, DMA was cleared from the blood within 12h 
post-administration, and its clearance increased throughout the treatment period. The results 
of cytotoxicity analysis in the hematological and hepatic cell lines (HL-60 and Huh 7) 
showed that DMA and MMA exert cytotoxic effects in both cells lines. The IC50 values in 
HL-60 and Huh 7 respectively were 20 mM and 52 mM for DMA and 44 mM and 70 mM 
for MMA. Furthermore, in vitro experiments showed that busulphan dissolved in DMA and 
combined with MMA exerted the most cytotoxic effects on Huh 7. We therefore compared 
the liver enzymes before and after busulphan conditioning and found the following: a 
significant increase in ALT, which is an enzyme indicating liver toxicity (Figure 6). 
Considering the relatively long half-life of MMA (≈ 12.7h), the presence of the 3 compounds 
(DMA, MMA and busulphan) at the same time in patients raises the question of possible 
combined toxicities. Additionally, the presence of MMA in patients’ blood for 40h after the 
end of busulphan conditioning should be investigated further for possible drug-drug 
interactions (DDI) with the next treatment. 
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Figure 6: Comparison of ALT levels before and after high-dose i.v busulphan in 18 patients. 
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3.   Study III  
Convulsions or busulphan-induced seizures, are one of the side effects associated with high-
dose busulphan conditioning [72]. Since approximately 10% of patients receiving high-dose 
busulphan experienced generalized seizures, prophylactic treatment was introduced 
concomitantly with the conditioning [71, 72, 124, 125]. The underlying mechanism of 
busulphan-induced seizures is not fully understood. In this study, we investigated the 
pharmacokinetics of busulphan and its metabolites, THT, THT 1-oxide, sulfolane, and 3OH-
sulfolane in 18 patients receiving high-dose treatment with busulphan. Although busulphan 
kinetics have been intensively studied, there is only little information available about the 
pharmacokinetics of its metabolites. The method developed by El-Serafi et al [61] has 
allowed us to follow the kinetics of these compounds in patients and mice. The results from 
this investigation have revealed accumulation of the two busulphan metabolites, sulfolane 
and 3-OH sulfolane, in plasma from patients. These two metabolites, particularly sulfolane, 
showed the highest plasma concentrations in patients; these levels remained relatively high 
and quantifiable even 40h after the last busulphan dose administration. It has been reported 
that sulfolane presented some neurotoxicities, such as hypothermia, in rodents [126], and we 
confirmed those findings in the group of mice intraperitoneally  injected with sulfolane. In 
addition to hypothermia, generalized seizures also occurred in mice administered with 
sulfolane. The pharmacokinetics of busulphan and its metabolites in mice organs showed 
that the highest ratio AUC brain/AUC plasma belonged to busulphan and sulfolane, 
indicating the high distribution of both compounds to the brain. The findings regarding the 
high levels of sulfolane measured in patients warrant for further investigations on the role of 
sulfolane in busulphan-induced neurotoxicities. Furthermore, these levels could raise 
questions about possible DDI between sulfolane and concomitant medications and/or the 
next treatment. The neurotransmitters measurements results have shown that Calbindin 28K 
levels were low in brains from sulfolane and 4 day busulphan groups, while GABA was 
reduced in the sulfolane group only. In fact, it has been reported previously that calcium-
binding protein levels were reduced in kindled rats [127]. Additionally, seizures are also 
associated with a decrease in the levels of inhibitory neurotransmitter GABA [128, 129]. In 
the counterpart, and given the anticonvulsant effect of dopamine, its high levels in the brain 
in the sulfolane and 4 day busulphan mice groups could have been for reversing the seizures 
[130-132]. 
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Figure 7: Plasma concentrations of busulphan metabolites in 18 patients throughout 
conditioning with busulphan and up to 72h after last dose administration. 
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4.   Study IV 
Busulphan is metabolized through GST-catalyzed conjugation with GSH; hence, the latter is 
depleted from hepatocytes by 60% in vivo and 50% in vitro[102]. In patients, it has been 
suggested that the depletion of GSH in the hepatocytes may augment the cyclophosphamide-
induced liver injury [133]. NAC is a precursor for GSH synthesis, and therefore it increases 
the cellular content of GSH [86]. NAC is widely used as a treatment to reverse 
acetaminophen toxicity [134], and it was suggested to be used as a treatment for SOS [135]. 
The main purpose of using NAC concomitantly with the busulphan conditioning is to 
enhance the GSH synthesis and prevent its depletion that might afterwards contribute to 
conditioning-related toxicities, particularly hepatotoxicity. Our study was retrospective; we 
followed the clinical outcome, conditioning/transplantation-related complications, and liver 
enzymes (AST, ALT, ALP, and Bilirubin) in 108 patients.  In this study, we compared a 
group of patients (n=54) that received conditioning using oral busulphan together with 
prophylactic treatment with NAC, to the second group that received oral busulphan without 
prophylactic treatment (control group). The clinical outcome of the transplantation was not 
affected by absence/presence of prophylaxis with NAC. However, the liver enzymes (ALT, 
AST, and ALP) were significantly decreased (normalized) after the end of busulphan 
conditioning in the NAC treated group, indicating less hepatotoxicity, compared to the 
untreated group (Figure 8). From these observations, we can conclude that NAC is a 
potential prophylactic treatment for hepatotoxicity during conditioning with busulphan. 
 
Figure 8: The mean aspartate transaminase (AST), alanine transaminase (ALT) and 
alkaline phosphatase (ALP) values before and after busulphan conditioning for patients 
treated with N-acetyl-l-cysteine (NAC) versus the control group.
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V.   CONCLUSIONS 
Study I 
•   We developed and validated, according to the FDA guidelines for bioanalytical 
method validation, a  sensitive and robust LC-MS based method for simultaneous 
quantification of DMA and MMA in plasma. 
•   The Method can be used for occupational exposure studies as well as monitoring 
DMA and MMA in patients receiving DMA-containing medications. 
Study II 
•   DMA clearance was increased throughout treatment with intravenous busulphan as 
part of the conditioning treatment prior to HSCT. 
•   MMA was accumulated in patients throughout the treatment period with busulphan 
and was still quantifiable 40h after the last dose administration of busulphan.  
•   The liver enzyme ALT levels were increased after the end of conditioning with 
intravenous busulphan. 
•   Hepatic-derived cells Huh 7 were more sensitive to the combination busulphan-
MMA than busulphan or MMA alone. 
•   Conditioning with intravenous busulphan, MMA might increase the busulphan-
induced hepatotoxicity. 
Study III 
•   Sulfolane, and to a lesser extent 3-OH sulfolane, exhibited accumulation in patients 
receiving busulphan prior to HSCT. 
•   Sulfolane induced generalized seizures in mice. 
•   The inhibitory nerotransmitter GABA and the calcium binding protein (Calbindin 
28K) were low in the group of mice injected with sulfolane. 
•   The busulphan-induced seizures might occur as a result of sulfolane accumulation in 
patients. 
Study IV 
•   NAC prophylaxis normalized the liver enzymes levels, ALT, AST and ALP in 
patients during treatment with busulphan prior to HSCT. 
•   The clinical outcome of the transplantation was NAC-independent. 
•   Prophylaxis with NAC might prevent busulphan-induced hepatotoxicity in patients 
undergoing HSCT. 
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